Full Press Release Details
Disrupting Convention in Women's Health Through Continuous Innovation January 2022 Corporate
Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans
and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will",
"would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.These forward-looking statements reflect management's beliefs and views with respect to
future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge
from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all of the forward-looking statements in
this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.Statements
contained herein are made as of the date of this Presentation unless stated otherwise, and neither this Presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is
correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.Certain information contained in this
Presentation relates to or is based statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates.
The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that
their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from
treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately
reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.This Presentation contains trademarks, trade names, or service marks
belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.
Femasys: At-a-Glance Who We Are Financial Information Femasys is a biomedical company aiming to
meet women's needs worldwide with a novel suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health.Headquarters: Suwanee, GA Nasdaq: FEMYIPO date: June 2021 (as of 09/30/21)Market
Cap: $81.3 M Cash: $27.28 M
Investment Highlights Biomedical Company Disrupting the Approaches to Women's Health with Proprietary
Diagnostic and Device Solutions in DevelopmentAddressing Multi-Billion Dollar Global Market Opportunities in Infertility and Permanent Birth Control With Differentiated and Improved ApproachesClear Reimbursement Path with Limited Competition
Yields Improved Patient Care and Health EconomicsWoman-Founded and Led, Experienced Leadership Team with Concentrated Development ExpertiseIn-House CMC and Device Infrastructure; 130+ Patents Filed Globally$33 million from recent IPO; early
investment from Medtronic
Our Product Pipeline Add anticipated milestones? - per Dory: Kathy will discuss stage and we can hold
this until later in the presentation Infertility Products and Product Candidates Contraception Product Candidate Biopsy Product Research Preclinical De Novo Clinical Study Approval PMA Clinical Studies Approval Stage
ISafety Stage IIValidation Stage IIIPivotal Research Preclinical Research Preclinical Research Preclinical THERAPEUTIC FemaSeed Localized Directional Insemination DIAGNOSTIC FemVue Contrast-Generating
Device FemCath Selective Delivery Catheter FemBloc Permanent Birth Control and Ultrasound Occlusion Confirmation FemCerv Endocervical Tissue Sampler
Broadly Applicable Proprietary Platform Technologies Our portfolio of products and product candidates
address various underserved areas of the reproductive and gynecological market providing solutions for OB/GYNS
Our Novel Biomedical Procedures in Development: Simple and In-Office Specified, precise delivery to
fallopian tubes (i.e., biomedical material, sperm or therapeutic agents) No anesthesia and no incisionsNo special skillset and no capital equipmentNo cannulation of tubePatents issued and pending Common minimally invasive technique(i.e.,
intrauterine catheters, IUD) Dual Placement Single Placement
Our Companion Ultrasound-Based Diagnostics: Simple and In-Office Balloon catheter insertedcommon
technique Deliver saline-air contrast for tubal evaluation Occlusion Patency No RadiationNo X-Ray DyeNo Referral to Radiology Center Contrast generation for screening and occlusion confirmation for use with our novel biomedical
procedures GLOBAL: Update with MOA time permitting
Strong Global IP Portfolio Our Patent Estate Encompasses Utility and Design 130+ patents ISSUED
globally; OVER 40 pending Directional Delivery (dual or single) to Fallopian Tubes Biopolymer Composition for Tubal Occlusion Contrast Generating Ultrasound Visible Tissue Sampling for Cancer Detection FemBloc, FemaSeed,
FemCath FemBloc FemVue FemCerv Occlusion Confirmation for FemBloc
FemBloc Permanent Birth Control + Ultrasound Occlusion Confirmation First and only non-surgical,
in-office, permanent birth control option in development with the potential to be the safest and most natural approach at half the cost of the long-standing surgical alternativeFirst in-office ultrasound approach for confirmation of procedure
Since surgical tubal ligation has been performed since the 1880's and remains the most common option for
women who want permanent birth control. Permanent Birth Control Alternatives: Unmet Need (U.S. only) >13M women no longer intend to have children >12M use non-permanent birth control, long-term 800,000 women choose surgical tubal
ligation as a form of permanent birth control every year More than 100 years of stagnant innovation for permanent birth control
Essure is a registered trademark of Bayer Healthcare (Conceptus) and, as of December 2018, no longer a
marketed solution. FemBloc: Expected Competitive Advantages Over Existing or Previous Birth Control Options On-Market Solutions Off-Market FemBloc Surgical Tubal
Ligation IUD(Reversible) Essure Permanent Office Procedure Some No Special Capital Equipment No Anesthesia No Coil Implant/ Clip No Hormones One-Time
Cost Multiple IUDs Worldwide Applicability Some
Companion ultrasound procedure exclusive to FemBloc confirms procedure success Occlusion
Confirmation No Permanent Implant - Scar Tissue Closes Tubal Lumen FemBloc Treatment FemBloc Permanent Birth Control in Development The first and only non-surgical, in-office approach Balloon at tubal opening without
cannulation Biopolymer is designed to be expelled within 3 months 3 Months Blockage Biopolymer solidifies Biopolymer degrades Saline-air contrast confirms blockage
Summary:n=183 subjects being followed for 5 years Patients found procedures highly tolerable 96%
physicians assessed procedure to be extremely/ very simple99% physicians assessed easier than tubal ligation surgery Summary:n=93 subjects received planned hysterectomy Subset with histopathology demonstrating biopolymer tissue reactionsNo
serious safety events reported Goals:n=50 subjects receive two confirmation tests to allow selection of ultrasound or radiology testEvaluate adequacy of improvements to procedures, products and training Goals:IDE approval of study
design(multi-center, unblinded prospective study)Previous FDA approved third-party study designs:primary endpoint of pregnancy rate at 1 year post confirmation testsafety follow-up 2-5 years post-market Safety & Effectivenessof
FemBloc Selection of ConfirmationTest for Pivotal No Serious AEs Reported Evaluated Delivery &Biopolymer Effectiveness FemBloc Clinical Studies for Pre-Market Approval (PMA) SITE RECRUITMENT UNDERWAY Early Clinical(completed) Stage
I: Safety(enrollment completed Feb 2019) Stage II: Validation(on-going) Stage III: Pivotal(pending)
165 27 53 8 2 2 3 5 12 1 FemBloc Treatment (90 days) FemBloc: Majority AEs Were Mild and
Occurred at Time of Procedure (n = 183 subjects) Patients are being followed for 5 years, with first subjects approaching 4-year follow-up 94% AEs related to device/ procedure occurred within 7 days of procedure 75% AEs mild No SAEs
Bleeding/Spotting (41.5%) Pain/Cramps
(38%) Other 28% 10.3% 2.1% 1.1% 24.8% 8.9% 4.3% 1.1% 1.8% *Visual Analog Scale (VAS) from 0-10 was used. FemBloc: Most Common Reported AEs (>1%) Were Related to Bleeding/Spotting or Pelvic Pain/Cramping Mean pain/ discomfort
score* as reported by patient: 4.3 for FemBloc treatment and 3.0 for confirmation
Permanent Birth Control Market Opportunity (U.S.) Near-Term Target Market $2B Annual Market Expansion
Opportunity $20 B Total Includes women (and partners) choosing permanent birth control annually (~1.3M) Includes women using non-permanent options but are candidates (>12M) Hormones Condoms Tubal Ligation Surgery 72 M Reproductive
Aged Women Most Invasive/ Most Reliable Least Invasive / Least Reliable
FemBloc: Improved Health Economics Permanent One-Time Cost Breakdown Pre-Op
$6,000* Facility Anesthesia Post-Op Cost of FemBloc System Anesthesia Physician / Practice Est < cost of Tubal Ligation Physician In-office procedure expands practice servicesCan perform multiple procedures in same roomQuicker
to perform and resume normal activities FemBloc Efficiencies Planned Parenthood 2019, https://www.plannedparenthood.org/learn/birth-control;Doximity 2019; U.S. Bureau of Labor Statistics, 2019.
In-office procedure FemBloc Treatment Category covered (ACA)Cat III code approved 2 FemBloc: Clear
Reimbursement Path 3 reimbursable office visits 1+ Days 3 Months In-office visit(required for permanent birth control) Counseling/Eligibility Existing CPT codes 1 In-office ultrasound procedure Cat III code approved FemBloc
FemaSeed Localized Directional Insemination Developing the first and only first-line approach designed
to deliver sperm where conception occursDesigned to be more affordable than assisted reproductionIncludes first in-office ultrasound diagnosis of fallopian tubes for infertility Companion Diagnostics FemVue and FemCath
Infertility: Unmet Need (U.S. only) More than 9 million struggle with infertility Despite
advancements, there have been no new affordable options in decades.
FemaSeed: Expected Competitive Advantages Over Existing Infertility Options FemaSeed Traditional
IUI IVF Artificial Insemination Sperm delivered directly to egg (FemaSeed via fallopian tube) Stimulation Drugs optional Low Procedure Cost Minimal Training
FemVue Diagnostic Evaluation of Fallopian Tubes Commercially Available FemCath Selective Fallopian
Tube Contrast Placement Commercially Available First diagnostic to allow for selective evaluation of a fallopian tube with contrast First diagnostic that creates natural contrast for an in-office ultrasound approach Companion Diagnostics
for FemaSeed Localized Directional Insemination Procedure
FemVue Saline-Air Device (used prior to FemaSeed Procedure) Diagnostic performed prior to infertility
proceduresCan be combined with saline evaluation of uterine cavity (standard of care)On-line training and support available for new customersPhysician locator available on patient websiteReimbursed using existing codes First In-office,
Ultrasound Approach for Fallopian Tube Evaluation Commercially Available: U.S., Europe, Canada, Japan When paired with FemCath allows for selective tubal evaluation Saline-Air contrast travels through the fallopian tube when open
FemaSeed Localized Directional Insemination in Development Limited advancements - continuous demand for
less costly options Undirected sperm delivery to cavity (IUI) is first line treatment despite low success rates First and only approach delivering sperm where conception occurs
FemaSeed: de Novo Pivotal LOCAL Clinical Trial IDE Approval Received April 2021 SITE RECRUITMENT
UNDERWAY Prospective, Multi-Center, Single-Arm (n=792 cycles) Confirmed clinical pregnancy with fetal heartbeat at 7 weeks post FemaSeed procedure Occurs at midpoint of data set Clinical Trial Design Interim Analysis: Primary
Effectiveness Endpoint:
Market Opportunity (U.S.) Near-Term Target Market $800M Total Market Expansion Opportunity $2B
Total Includes women choosing IUI and required tubal diagnosis Intrauterine Insemination (IUI) Diagnosis / Drugs Discussion Only IVF(~200k/ year) >9M Infertile Women Most Expensive Least Expensive
FemaSeed Potential Market Penetration U.S. Commercial Strategy Goals: No Advancement for Decades
and Limited Competition in the Infertility Product Category 1,300 reproductive endocrinologists at 450 practices Hire direct sales force for U.S., distribution partners for internationalInitially target customers for FemVue (50 practices
currently)8 states represent over 50% practices and 60% of assisted reproductive cycles Prospective Targets
FemCerv Diagnostic/Cervical Cancer Sampling First endocervical biopsy designed for comprehensive
tissue sampling with minimal contamination FDA Approved Commercialization Pending
Expanded Collection Chamber FemCerv: Diagnostic Cervical Screening Solution First cervical tissue
sampler designed to improve tissue quality and quantity 1 Designed for minimal contaminationAllows for comprehensive tissue samplingDesigned to minimize patient discomfort 2 Collected sample
Our Strategy: Targeting Ob/Gyns With Product Solutions Throughout the Continuum of Female
Care Addressing facets of care that have had negligible advancement over decades to create improved patient care and improved physician treatment options Procedures for Infertility/Permanent Birth Control Diagnostic Evaluation Occlusion
Confirmation for FemBloc and FemCerv FemVue and FemCath FemaSeed and FemBloc Diagnostic Confirmation and Ongoing Care
Our Strategy: Targeting Ob/Gyns With Product Solutions Throughout the Continuum of Female Care U.S.